Chi Sheng Pharma & Biotech Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chi Sheng Pharma & Biotech.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	48.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Chi Sheng Pharma & Biotech no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

TPEX:4111 - Estimaciones futuras de los analistas y datos financieros pasados (TWD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2024	1,082	73	24	132	N/A
3/31/2024	1,065	73	-67	47	N/A
12/31/2023	1,061	69	-27	75	N/A
9/30/2023	1,090	116	9	111	N/A
6/30/2023	1,115	151	89	197	N/A
3/31/2023	1,130	164	107	225	N/A
12/31/2022	1,143	179	109	215	N/A
9/30/2022	1,105	186	128	216	N/A
6/30/2022	1,085	150	-73	197	N/A
3/31/2022	1,059	129	-100	164	N/A
12/31/2021	1,022	108	-126	139	N/A
9/30/2021	1,003	56	-137	125	N/A
6/30/2021	971	41	61	103	N/A
3/31/2021	953	46	87	109	N/A
12/31/2020	979	59	121	144	N/A
9/30/2020	1,005	72	101	129	N/A
6/30/2020	1,026	80	152	177	N/A
3/31/2020	1,047	85	179	206	N/A
12/31/2019	1,023	72	126	163	N/A
9/30/2019	998	57	131	187	N/A
6/30/2019	985	57	69	134	N/A
3/31/2019	964	46	18	87	N/A
12/31/2018	967	42	38	114	N/A
9/30/2018	985	52	34	98	N/A
6/30/2018	1,016	60	63	133	N/A
3/31/2018	1,032	69	N/A	157	N/A
12/31/2017	1,045	82	N/A	181	N/A
9/30/2017	1,034	91	N/A	162	N/A
6/30/2017	1,012	88	N/A	160	N/A
3/31/2017	995	85	N/A	133	N/A
12/31/2016	964	73	N/A	104	N/A
9/30/2016	946	48	N/A	130	N/A
6/30/2016	936	46	N/A	120	N/A
3/31/2016	938	42	N/A	116	N/A
12/31/2015	932	39	N/A	97	N/A
9/30/2015	908	40	N/A	92	N/A
6/30/2015	922	50	N/A	89	N/A
3/31/2015	925	59	N/A	116	N/A
12/31/2014	943	73	N/A	147	N/A
9/30/2014	979	104	N/A	167	N/A
6/30/2014	974	105	N/A	177	N/A
3/31/2014	960	106	N/A	188	N/A
12/31/2013	921	96	N/A	143	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if 4111's forecast earnings growth is above the savings rate (1%).

Beneficios vs. Mercado: Insufficient data to determine if 4111's earnings are forecast to grow faster than the TW market

Beneficios de alto crecimiento: Insufficient data to determine if 4111's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if 4111's revenue is forecast to grow faster than the TW market.

Ingresos de alto crecimiento: Insufficient data to determine if 4111's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if 4111's Return on Equity is forecast to be high in 3 years time

Chi Sheng Pharma & Biotech Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.36 in 2Q 2023)

Dividend reduced to NT$1.00

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 23%

Now 28% overvalued after recent price rise

First quarter 2024 earnings released: EPS: NT$0.41 (vs NT$0.33 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$1.21 (vs NT$3.15 in FY 2022)

Chi Sheng Pharma & Biotech Co., Ltd, Annual General Meeting, Jun 13, 2024

New minor risk - Profit margin trend

Upcoming dividend of NT$1.20 per share at 4.5% yield

Second quarter 2023 earnings released: EPS: NT$0.36 (vs NT$0.46 in 2Q 2022)

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: NT$3.14 (vs NT$1.42 in FY 2021)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS NT$0.39 (vs NT$0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.21 (vs NT$0.28 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.46 in 1Q 2020)

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Full year 2020 earnings released: EPS NT$1.04 (vs NT$1.27 in FY 2019)

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$22.80

New 90-day low: NT$23.30

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Third quarter 2020 earnings released: EPS NT$0.14

New 90-day low: NT$24.00

New 90-day low - NT$24.40

First half earnings released

First half earnings released

New 90-day low - NT$25.55

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento